Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
01:00am, Thursday, 30'th Apr 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
01:01pm, Wednesday, 29'th Apr 2026
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
11:21am, Wednesday, 29'th Apr 2026
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Roche: Policy Overhang Clears, Fundamentals Intact, Upside Remains Limited But Positive
10:08am, Tuesday, 28'th Apr 2026
US healthcare policy overhang has largely abated after MFN pricing deals, improving sector sentiment and reducing drug pricing risk for Roche and peers. Q1 showed solid underlying growth (+6% CER), su
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign developed in partnership with adv
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript
06:31pm, Thursday, 23'rd Apr 2026
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
12:50pm, Thursday, 23'rd Apr 2026
Roche's Q1 beat masks currency drag as strong drug demand drives CER growth and offsets biosimilar hit to legacy portfolio.
Iran won't give up its “new nuclear weapon” - the Strait of Hormuz: David Roche
02:51am, Thursday, 23'rd Apr 2026
David Roche of Quantum Strategy warns of a 3% global economic decline as tankers halt movement through the Gulf and Red Sea. He further argues that markets are disconnected from reality, underestimati
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
02:50am, Thursday, 23'rd Apr 2026
Roche sales fell 5% in the first quarter, but increased 6% in constant exchange rates. The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on
Roche Backs Full-Year View as Quarterly Sales Rise
01:33am, Thursday, 23'rd Apr 2026
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
01:12am, Thursday, 23'rd Apr 2026
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharma
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
12:20am, Thursday, 23'rd Apr 2026
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
12:46pm, Wednesday, 22'nd Apr 2026
RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
01:25am, Wednesday, 22'nd Apr 2026
Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals while data released on Wedn
